Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. Keeping that in mind, here is one value stock with strong fundamentals and two facing an uphill battle.
Two Value Stocks to Sell:
AMC Networks (AMCX)
Forward P/E Ratio: 2.8x
Originally the joint-venture of four cable television companies, AMC Networks (NASDAQ:AMCX) is a broadcaster producing a diverse range of television shows and movies.
Why Do We Pass on AMCX?
- Sales tumbled by 5% annually over the last five years, showing consumer trends are working against it
- Low free cash flow margin of 10.3% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
AMC Networks is trading at $11 per share, or 2.8x forward P/E. To fully understand why you should be careful with AMCX, check out our full research report (it’s free).
Amphastar Pharmaceuticals (AMPH)
Forward P/E Ratio: 7.2x
Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ:AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.
Why Does AMPH Worry Us?
- Muted 3.2% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
- Smaller revenue base of $720.5 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Costs have risen faster than its revenue over the last two years, causing its adjusted operating margin to decline by 10.9 percentage points
At $20.28 per share, Amphastar Pharmaceuticals trades at 7.2x forward P/E. Check out our free in-depth research report to learn more about why AMPH doesn’t pass our bar.
One Value Stock to Buy:
EXL (EXLS)
Forward P/E Ratio: 14.2x
Originally founded as an outsourcing company in 1999 before evolving into a technology-focused enterprise, EXL (NASDAQ:EXLS) provides data analytics and AI-powered digital operations solutions that help businesses transform their operations and make better decisions.
Why Is EXLS a Good Business?
- Market share has increased this cycle as its 16.9% annual revenue growth over the last five years was exceptional
- Expected revenue growth of 14.3% for the next year suggests its market share will rise
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 19% exceeded its revenue gains over the last five years
EXL’s stock price of $33.88 implies a valuation ratio of 14.2x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like Find your next big winner with StockStory today.